Influenza News and Research

Latest Influenza News and Research

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A recent study conducted at the Ohio State University, USA, and the Fudan University, China, has revealed that alpha-defensin human neutrophil peptide 1 (HNP1), a cationic antimicrobial peptide, can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from infecting cells by destabilizing the viral spike protein and disrupting spike-mediated viral envelop – host cell membrane fusion.

31 May 2021

Reusing old vaccines to boost innate immunity against COVID-19

The COVID-19 vaccine is currently the best form of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. But a new perspective article published in the journal PNAS suggests it’s not the panacea to stopping SARS-CoV-2.

31 May 2021

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.

28 May 2021

Researchers discover cross-reactive coronavirus antibody triggered during COVID-19 infection

Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one.

28 May 2021

New favipiravir derivative is a potent SARS-CoV-2 inhibitor

In a new study recently published in Chemical Papers by Dr. Amgad Rabie (May 16th, 2021), a high potency derivative of favipiravir towards SARS-CoV-2 is engineered and investigated.

27 May 2021

New DNA COVID-19 vaccine proven effective in mice

A new study has shown that a new DNA-based COVID-19 vaccine successfully induced immunization against SARS-CoV-2 in mice and hamsters.

27 May 2021

Study shows more evidence that vaccines are safe for children, adults

A new study looking across a large body of research finds further evidence for the safety of vaccines that are Food and Drug Administration-approved and routinely recommended for children, adults and pregnant women.

27 May 2021

Can certain aircraft boarding procedures increase SARS-CoV-2 transmission risks?

In a study published in the Royal Society Open Science journal, researchers simulated many aircraft boarding processes to assess their impact on social proximity during boarding. They also studied the dominant mechanisms by which these processes generate social proximity. The researchers systematically measured proximity by measuring the number of contacts originating from the following situations: 1. contacts between seated passenger pairs; 2. contacts between aisle passenger pairs; and 3. contacts between a seated passenger and an aisle passenger.

26 May 2021

Zoonotic and vector-borne emerging tropical diseases pose a constant threat

A recent article published in the journal Frontiers in Tropical Diseases assessed the threat of emerging zoonotic and vector-borne tropical diseases.

26 May 2021

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.

26 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers compared the nasal microbiome of coronavirus disease 2019 (COVID-19) patients, healthy individuals, and healthcare workers. These studies indicated an increase in the pathogen Pseudomonas aeruginosa present in the nasal microbiome of COVID-19 patients, which may be responsible for other secondary infections.

24 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

New peptide-like molecules could treat herpes, COVID-19, and the common cold

Among the powerful biochemicals of the human immune system, peptides are one of the best.

24 May 2021

Reduced levels of leptin are linked to poor vaccine responses in general population

Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found.

24 May 2021

Australian discovery could speed up SARS-CoV-2 vaccine development

To address this gap, researchers from Australia recently examined the relationship between levels of in vitro neutralization and the observed protection obtained from SARS-CoV-2 infection. They used data from 7 currently available vaccines and convalescent cohorts. Their research is published in the journal Nature Medicine.

22 May 2021